



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07D 239/94 ^(2006.01) **C07D 487/04** ^(2006.01)
A61K 31/517 ^(2006.01) **A61K 31/519** ^(2006.01)
A61P 35/00 ^(2006.01) **A61P 35/02** ^(2006.01)
A61P 19/00 ^(2006.01) **A61P 9/00** ^(2006.01)
A61P 17/00 ^(2006.01)

(48) Corrigendum issued on:
08.09.2021 Bulletin 2021/36

(45) Date of publication and mention
of the grant of the patent:
14.07.2021 Bulletin 2021/28

(21) Application number: **19170210.9**

(22) Date of filing: **28.11.2008**

(54) **SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE**

KLEINMOLEKÜLIGE MYRISTATINHIBITOREN VON BCR-ABL UND VERFAHREN ZUR
VERWENDUNG

INHIBITEURS DE MYRISTATE DE BCR-ABL À PETITE MOLÉCULE ET PROCÉDÉS D'UTILISATION

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**

(30) Priority: **28.11.2007 US 4462 P**

(43) Date of publication of application:
11.09.2019 Bulletin 2019/37

(60) Divisional application:
21184206.7

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
16197611.3 / 3 150 593
08857261.5 / 2 222 162

(73) Proprietors:
• **Dana-Farber Cancer Institute, Inc.**
Boston, MA 02215 (US)
• **The Scripps Research Institute**
La Jolla, CA 92037 (US)

(72) Inventors:
• **GRAY, Nathanael S.**
Boston, MA 02130 (US)
• **ZHANG, Jianming**
Belmont, MA 02478 (US)
• **OKRAM, Barun**
San Marcos, CA 92078 (US)

(74) Representative: **Heller, Benjamin Henry**
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL (GB)

(56) References cited:
WO-A1-00/56720 WO-A2-03/040144
WO-A2-2005/039486

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).